S70 Antimicrobial susceptibility pattern of nosocomial urinary tract infections in patients with spinal cord injury in a rehabilitation setting

2013 ◽  
Vol 12 (4) ◽  
pp. e1178, S70
Author(s):  
O. Sezer ◽  
K. Erten ◽  
U. Güzelküçük ◽  
B. Yılmaz ◽  
A.K. Tan
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Antimicrobial Susceptibility ◽  
Susceptibility Pattern ◽  
Antimicrobial Susceptibility Pattern ◽  
Cord Injury ◽  
Tract Infections

Decreased Incidence of Urinary Tract Infections in Patients with Spinal Cord Injury: Effect of Methenamine

1991 ◽  
Vol 14 (2) ◽  
pp. 52-54 ◽  
Author(s):  
K. Banovac ◽  
Nancy Wade ◽  
F. Gonzalez ◽  
Bridget Walsh ◽  
R.K. Rhamy
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Cord Injury ◽  
Tract Infections

Antibiotic cycling prevents urinary tract infections in spinal cord injury patients and limits the emergence of multidrug resistant organism

2015 ◽  
Vol 71 (4) ◽  
pp. 491-493 ◽  
Author(s):  
Claire Poirier ◽  
Aurélien Dinh ◽  
Jérôme Salomon ◽  
Nathalie Grall ◽  
Antoine Andremont ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Multidrug Resistant ◽  
Resistant Organism ◽  
Cord Injury ◽  
Antibiotic Cycling ◽  
Tract Infections

scholarly journals Immunosenescence in persons with spinal cord injury in relation to urinary tract infections -a cross-sectional study-

2017 ◽  
Vol 14 (1) ◽  
Author(s):  
David Pavlicek ◽  
Jörg Krebs ◽  
Simona Capossela ◽  
Alessandro Bertolo ◽  
Britta Engelhardt ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Cord Injury ◽  
Tract Infections

scholarly journals Immunomodulation for primary prevention of urinary tract infections in patients with spinal cord injury during primary rehabilitation: protocol for a randomized placebo-controlled pilot trial (UROVAXOM-pilot)

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Jörg Krebs ◽  
Jivko Stoyanov ◽  
Jens Wöllner ◽  
Ezra Valido ◽  
Jürgen Pannek
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Pilot Trial ◽  
Lower Urinary Tract Dysfunction ◽  
E Coli ◽  
Link Type ◽  
Cord Injury ◽  
Tract Infections

Abstract Background Urinary tract infections (UTIs) are common in individuals with neurogenic lower urinary tract dysfunction (NLUTD) following spinal cord injury (SCI). They are not only a great burden for affected individuals, but also cause considerable health costs. Furthermore, recurrent antibiotic treatments of UTIs contribute to the growing problem of bacterial resistance to antimicrobial compounds. Even though there is a multitude of different measures to prevent UTIs in individuals with NLUTD, no clear evidence exists for any of these. Oral immunomodulation with UTI-relevant Escherichia coli lysate may be a promising preventative measure with a good safety profile in individuals with NLUTD. However, currently available data are sparse. Methods This is a randomized, quasi-blinded, placebo-controlled, mono-centric pilot trial investigating the feasibility of a main trial regarding the effects of a lyophilized lysate of E. coli strains for oral application (Uro-Vaxom®, OM Pharma SA, Meyrin, Switzerland). There will be two parallel groups of 12 participants each. Individuals with acute SCI (duration SCI ≤ 56 days) from 18 to 70 years of age admitted for primary rehabilitation will be eligible. Blood and urine samples will be taken prior to intervention start, at the end of the intervention, and 3 months after intervention termination. The trial intervention will last 90 days. The participants will not be informed regarding the treatment allocation (quasi-blinded). The nursing staff will prepare the daily dose of the allocated treatment from the original packaging. The trial personnel and the biostatistician will be blinded. Feasibility (e.g., recruitment rate, patient attrition), clinical (e.g., number of symptomatic UTIs), and laboratory parameters (e.g., urinary culture, urinary proteo- and microbiome, blood cell counts) as well as adverse events will be collected. Discussion Effective and efficient measures for the prevention of UTIs in individuals with NLUTD are urgently needed. If the conclusion of this pilot is positive regarding feasibility, the effects of oral immunomodulation with a E. coli lysate will be investigated in a larger, sufficiently powered, multi-center trial. Trial registration ClinicalTrials.govNCT04049994. Registered on 8 August 2019

Sign in / Sign up

Export Citation Format

Share Document